Data from a clinical trial of amyotrophic lateral sclerosis (ALS) patients treated with stem cell technology reveals that the therapy has proven safe without causing significant side effects. Patients in the trial were transplanted with stem cells derived from their own bone marrow and treated with BrainStorm Cell Therapeutics’s NurOwn stem cell therapy. The initial phase of the study is designed to establish the safety of NurOwn and will later be expanded to assess efficacy.
